Selective reduction of AKR1C2 in prostate cancer and its role in DHT metabolism

Prostate

Volumn 54, Issue 4, 2003, Pages 275-289

  Ji, Qing ^a   Chang, Lilly ^a   VanDenBerg, David ^a   Stanczyk, Frank Z ^a   Stolz, Andrew ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Hoffman Medical Research   (United States)

Author keywords

AKR1C1; AKR1C2; Androgen metabolism; Prostate cancer; Real time PCR

Indexed keywords

ALDOKETOREDUCTASE 1C; ANDROSTANEDIOL; ANDROSTANOLONE; MESSENGER RNA; OXIDOREDUCTASE; STEROID 5ALPHA REDUCTASE; UNCLASSIFIED DRUG;

ANDROGEN METABOLISM; ARTICLE; CANCER CELL CULTURE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOCHEMISTRY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

20-HYDROXYSTEROID DEHYDROGENASES; 3-ALPHA-HYDROXYSTEROID DEHYDROGENASE (B-SPECIFIC); 3-HYDROXYSTEROID DEHYDROGENASES; ANDROGENS; CARCINOMA, HEPATOCELLULAR; CHOLESTENONE 5 ALPHA-REDUCTASE; DIHYDROTESTOSTERONE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXYSTEROID DEHYDROGENASES; MALE; OXIDOREDUCTASES; POLYMERASE CHAIN REACTION; PROSTATE; PROSTATIC NEOPLASMS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0037372349     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10192     Document Type: Article

References (65)

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000;50:7-33.
2. Ross RK, Schottenfeld D, Schottenfeld D, Fraumeni J, editors. Cancer epidemiology and prevention. Oxford, England: Oxford University Press; 1996. pp 1180-1206.
3. Ross RK, Pike MC, Coetzee GA, Reichardt JK, Yu MC, Feigelson H, Stanczyk FZ, Kolonel LN, Henderson BE. Androgen metabolism and prostate cancer: Establishing a model of genetic susceptibility. Cancer Res 1998;58:4497-4504.
4. Pike MC, Spicer DV, Dahmoush L, Press MF. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 1993;15:17-35.
5. Henderson BE, Ross RK, Pike MC. Hormonal chemoprevention of cancer in women. Science 1993;259:633-638.
6. Smith LL, Brown K, Carthew P, Lim CK, Martin EA, Styles J, White IN. Chemoprevention of breast cancer by tamoxifen: Risks and opportunities. Crit Rev Toxicol 2000;30:571-594.
7. Oesterling JE, Fuks Z, Lee CT, Scher HI. Cancer of the prostate. In: Devita VT, Hellman S, Rosenberg SA, editors. Cancer principles and practice of oncology. 5 edn; Philadelphia: 1997. pp 1322-1375.
8. Isaacs JT. Role of androgens in prostatic cancer. Vitamin Horm 1994;49:433-502.
9. Feigelson HS, Ross RK, Yu MC, Coetzee GA, Reichardt JK, Henderson BE. Sex steroid hormones and genetic susceptibility to breast and prostate cancer. Drug Metab Rev 1998;30:421-434.
10. Dorkin TJ, Neal DE. Basic science aspects of prostate cancer. Semin Cancer Biol 1997;8:21-27.
11. Brown TR. Provocative aspects of androgen genetics. Prostate Suppl 1996;6:9-12.
12. Galbraith SM, Duchesne GM. Androgens and prostate cancer: Biology, pathology and hormonal therapy. Eur J Cancer 1997;33:545-554.
13. Roy AK, Chatterjee B. Androgen action. Crit Rev Eukaryot Gene Expr 1995;5:157-176.
14. Russell DW, Berman DM, Bryant JT, Cala KM, Davis DL, Landrum CP, Prihoda JS, Silver RI, Thigpen AE, Wigley WC. The molecular genetics of steroid 5 alpha-reductases. Recent Prog Horm Res 1994;49:275-284.
15. Thigpen AE, Davis DL, Milatovich A, Mendonca BB, Imperato-McGinley J, Griffin JE, Francke U, Wilson JD, Russell DW. Molecular genetics of steroid 5 alpha-reductase 2 deficiency. J Clin Invest 1992;90:799-809.
16. Labrie F, Dupont A, Simard J, Luu-The V, Belanger A. Intracrinology: the basis for the rational design of endocrine therapy at all stages of prostate cancer. Eur Urol 1993;24:94-105.
17. Labrie F, Luu-The V, Lin SX, Simard J, Labrie C, El-Alfy M, Pelletier G, Belanger A. Intracrinology: Role of the family of 17 beta-hydroxysteroid dehydrogenases in human physiology and disease. J Mol Endocrinol 2000;25:1-16.
18. Reichardt JK. GEN GEN: The genomic genetic analysis of androgen-metabolic genes and prostate cancer as a paradigm for the dissection of complex phenotypes. Front Biosci 1999;4:D596-D600.
19. Makridakis NM, Ross RK, Pike MC, Crocitto LE, Kolonel LN, Pearce CL, Henderson BE, Reichardt JK. Association of missense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet 1999;354:975-998.
20. Xue W, Irvine RA, Yu MC, Ross RK, Coetzee GA, Ingles SA. Susceptibility to prostate cancer: Interaction between genotypes at the androgen receptor and prostate-specific antigen loci. Cancer Res 2000;60:839-841.
21. Monroe KR, Yu MC, Kolonel LN, Coetzee GA, Wilkens LR, Ross RK, Henderson BE. Evidence of an X-linked or recessive genetic component to prostate cancer risk. Nat Med 1995;1:827-829.
22. Ingles SA, Ross RK, Yu MC, Irvine RA, La Pera G, Haile RW, Coetzee GA. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 1997;89:166-170.
23. Lin H-K, Jez JM, Schlegel BP, Peehl DM, Pachter JA, Penning TM. Expression and characterization of recombinant type-2 3 alpha hydroxysteroid dehydrogenase (HSD) from human postate - Demonstration of bifunctional 3-alpha/17-beta-HSD activity and cellular distribution. Mol Endocrinol 1997;11:1971-1984.
24. Dufort I, Labrie F, Luu-The V. Human types 1 and 3 alpha-hydroxysteroid dehydrogenases: Differential lability and tissue distribution. J Clin Endocrinol Metab 2001;86:841-886.
25. Dufort I, Rheault P, Huang XF, Soucy P, Luu-The V. Characteristics of a highly labile human type 5 17beta-hydroxysteroid dehydrogenase. Endocrinology 1999;140:568-5674.
26. Khanna M, Qin KN, Wang RW, Cheng KC. Substrate specificity, gene structure, and tissue-specific distribution of multiple human 3 alpha-hydroxysteroid dehydrogenases. J Biol Chem 1995;270:20162-20168.
27. Dufort I, Soucy P, Labrie F, Luu-The V. Molecular cloning of human type 3 3α-hydroxysteroid dehydrogenase that differs from 20α-hydroxysteroid dehydrogenase by seven amino acids. Biochem Biophys Res Commun 1996;228:474-479.
28. Hara A, Matsuura K, Tamada Y, Sato K, Miyabe Y, Deyashiki Y, Ishida N. Relationship of human liver dihydrodiol dehydrogenases to hepatic bile- acid-binding protein and an oxidoreductase of human colon cells. Biochem J 1996;313:373-376.
29. Deyashiki Y, Ogasawara A, Nakayama T, Nakanishi M, Miyabe Y, Sato K, Hara A. Molecular cloning of two human liver 3 alpha-hydroxysteroid/dihydrodiol dehydrogenase isoenzymes that are identical with chlordecone reductase and bile-acid binder. Biochem J 1994;299:545-552.
30. Nahoum V, Gangloff A, Legrand P, Zhu DW, Cantin L, Zhorov B, Luu-The V, Labrie F, Breton R, Lin SX. Structure of the human 3alpha-HSD type 3 in complex with testosterone and NADP at 1.25 Å resolution. J Biol Chem 2001;276:42091-42098.
31. Stolz A, Sugiyama Y, Kuhlenkamp J, Kaplowitz N. Identification and purification of a 36 kDa bile acid binder in human hepatic cytosol. FEBS Lett 1984;177:31-35.
32. Jez JM, Flynn TG, Penning TM. A new nomenclature for the aldoketo reductase superfamily. Biochem Pharmacol 1997;54:639-647.
33. Stolz A, Hammond L, Lou H, Takikawa H, Ronk M, Shively JE. cDNA cloning and expression of the human hepatic bile acid-binding protein. A member of the monomeric reductase gene family. J Biol Chem 1993;268:10448-10457.
34. Hara A, Taniguchi H, Nakayama T, Sawada H. Purification and properties of multiple forms of dihydrodiol dehydrogenase from human liver. J Biochem (Tokyo) 1990;108:250-254.
35. Penning TM, Burczynski ME, Jez JM, Hung CF, Lin HK, Ma H, Moore M, Palackal N, Ratnam K. Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: Functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochem J 2000;351:67-77.
36. Shiraishi H, Ishikura S, Matsuura K, Deyashiki Y, Ninomiya M, Sakai S, Hara A. Sequence of the cDNA of a human dihydrodiol dehydrogenase isoform (AKR1C2) and tissue distribution of its mRNA. Biochem J 1998;334:399-405.
37. Penning TM. Molecular endocrinology of hydroxysteroid dehydrogenases. Endocr Rev 1997;18:281-305.
38. Lou H, Hammond L, Sharma V, Sparkes RS, Lusis AJ, Stolz A. Genomic organization and chromosomal localization of a novel human hepatic dihydrodiol dehydrogenase with high affinity bile acid binding. J Biol Chem 1994;269:8416-8422.
39. Serafini P, Ablan F, Lobo RA. 5 alpha-Reductase activity in the genital skin of hirsute women. J Clin Endocrinol Metab 1985;60:349-355.
40. Nguyen TT, Nguyen CT, Gonzales FA, Nichols PW, Yu MC, Jones PA. Analysis of cyclin-dependent kinase inhibitor expression and methylation patterns in human prostate cancers. Prostate 2000;43:233-242.
41. Tchernof A, Levesque E, Beaulieu M, Couture P, Despres JP, Hum DW, Belanger A. Expression of the androgen metabolizing enzyme UGT2B15 in adipose tissue and relative expression measurement using a competitive RT-PCR method. Clin Endocrinol (Oxf) 1999;50:637-642.
42. Latil A, Bieche I, Vidaud D, Lidereau R, Berthon P, Cussenot O, Vidaud M. Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res 2001;61:1919-1926.
43. Lehmann U, Glockner S, Kleeberger W, von Wasielewski HF, Kreipe H. Detection of gene amplification in archival breast cancer specimens by laser-assisted microdissection and quantitative real-time polymerase chain reaction. Am J Pathol 2000;156:1855-1864.
44. Ji Q, Chen Y. Vicia faba root tip micronucleus test on the mutagenicity of water-soluble contents of cigarette smoke. Mutat Res 1996;359:1-6.
45. Webber MM, Bello D, Quader S. Immortalized and tumorigenic adult human prostatic epithelial cell lines: Characteristics and applications. Part 3. Oncogenes, suppressor genes, and applications. Prostate 1997;30:136-142.
46. Montgomery BT, Young CY, Bilhartz DL, Andrews PE, Prescott JL, Thompson NF, Tindall DJ. Hormonal regulation of prostate-specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line, LNCaP. Prostate 1992;21:63-73.
47. Takikawa H, Stolz A, Kaplowitz N. Cyclical oxidation-reduction of the C3 position on bile acids catalyzed by rat hepatic 3 alpha-hydroxysteroid dehydrogenase. I. Studies with the purified enzyme, isolated rat hepatocytes, and inhibition by indomethacin. J Clin Invest 1987;80:852-860.
48. Stolz A, Takikawa H, Sugiyama Y, Kuhlenkamp J, Kaplowitz N. 3 alpha-hydroxysteroid dehydrogenase activity of the Y′ bile acid binders in rat liver cytosol. Identification, kinetics, and physiologic significance. J Clin Invest 1987;79:427-434.
49. Khanna M, Qin KN, Klisak I, Belkin S, Sparkes RS, Cheng KC. Localization of multiple human dihydrodiol dehydrogenase (DDH1 and DDH2) and chlordecone reductase (CHDR) genes in chromosome 10 by the polymerase chain reaction and fluorescence in situ hybridization. Genomics 1995;25:588-590.
50. Seery LT, Nestor PV, FitzGerald GA. Molecular evolution of the aldo-keto reductase gene superfamily. J Mol Evol 1998;46:139-146.
51. el-Kabbani O, Judge K, Ginell SL, Myles DA, DeLucas LJ, Flynn TG. Structure of porcine aldehyde reductase holoenzyme. Nat Struct Biol 1995;2:687-692.
52. Wilson DK, Nakano T, Petrash JM, Quiocho FA. 1.7 A structure of FR-1, a fibroblast growth factor-induced member of the aldo-keto reductase family, complexed with coenzyme and inhibitor. Biochemistry 1995;34:14323-14330.
53. Petrash JM, Tarle I, Wilson DK, Quiocho FA. Aldose reductase catalysis and crystallography. Insights from recent advances in enzyme structure and function. Diabetes 1994;8:955-959.
54. Bennett MJ, Albert RH, Jez JM, Ma H, Penning TM, Lewis M. Steroid recognition and regulation of hormone action: crystal structure of testosterone and NADP+ bound to 3 alpha-hydroxysteroid/dihydrodiol dehydrogenase. Structure 1997;5:799-812.
55. Jin Y, Stayrook SE, Albert RH, Palackal NT, Penning TM, Lewis M. Crystal structure of human type III 3alpha-hydroxysteroid dehydrogenase/bile acid binding protein complexed with NADP(+) and ursodeoxycholate. Biochemistry 2001;40:10161-10168.
56. Stolz A, Sugiyama Y, Kuhlenkamp J, Osadchey B, Yamada T, Belknap W, Balistreri W, Kaplowitz N. Cytosolic bile acid binding protein in rat liver: Radioimmunoassay, molecular forms, developmental characteristics and organ distribution. Hepatology 1986;6:433-439.
57. Takikawa H, Stolz A, Sugimoto M, Sugiyama Y, Kaplowitz N. Comparison of the affinities of newly identified human bile acid binder and cationic glutathione S-transferase for bile acids. J Lipid Res 1986;27:652-657.
58. Takikawa H, Stolz A, Sugiyama Y, Yoshida H, Yamanaka M, Kaplowitz N. Relationship between the newly identified bile acid binder and bile acid oxidoreductases in human liver. J Biol Chem 1990;265:2132-2136.
59. Guillemette C, Hum DW, Belanger A. Regulation of steroid glucuronosyltransferase activities and transcripts by androgen in the human prostatic cancer LNCaP cell line. Endocrinology 1996;137:2872-2879.
60. Pelletier G, Luu-The V, Tetu B, Labrie F. Immunocytochemical localization of type 5 17beta-hydroxysteroid dehydrogenase in human reproductive tissues. J Histochem Cytochem 1999;47:731-738.
61. Soderstrom TG, Bjelfman C, Brekkan E, Ask B, Egevad L, Norlen BJ, Rane A. Messenger ribonucleic acid levels of steroid 5 alpha-reductase 2 in human prostate predict the enzyme activity. J Clin Endocrinol Metab 2001;86:855-858.
62. Bjelfman C, Soderstrom TG, Brekkan E, Norlen BJ, Egevad L, Unge T, Andersson S, Rane A. Differential gene expression of steroid 5 alpha-reductase 2 in core needle biopsies from malignant and benign prostatic tissue. J Clin Endocrinol Metab 1997;82:2210-2214.
63. Iehle C, Radvanyi F, Gil Diez de Medina S, Ouafik LH, Gerard H, Chopin D, Raynaud JP, Martin PM. Differences in steroid 5alpha-reductase iso-enzymes expression between normal and pathological human prostate tissue. J Steroid Biochem Mol Biol 1999;68:189-195.
64. Akalu A, Dlmajian DA, Highshaw RA, Nichols PW, Reichardt JK. Somatic mutations at the SRD5A2 locus encoding prostatic steroid 5alpha-reductase during prostate cancer progression. Journal of Urology 1999;161:1355-1358.
65. Chetcuti A, Margan S, Mann S, Russell P, Handelsman D, Rogers J, Dong Q. Identification of differentially expressed genes in organ-confined prostate cancer by gene expression array. Prostate 2001;47:132-140.